Vaccines for the prevention of dengue: Development update

Human Vaccines

Volumn 7, Issue 6, 2011, Pages 674-684

  Thomas, Stephen J ^a,b   Endy, Timothy P ^a,b  

^a ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^b State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

Clinical; Dengue; Development; Pre clinical; Vaccine

Indexed keywords

ADENOVIRUS VECTOR; ANTIVIRUS AGENT; CHIMERIVAX; DEN1-80E; DENGUE VACCINE; DENVAX; DNA VACCINE; HYBRID PROTEIN; JAPANESE ENCEPHALITIS VACCINE; LIVE VACCINE; PLACEBO; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS VACCINE; YELLOW FEVER VACCINE;

ANTIBODY PRODUCTION; CHIMERA; DENGUE; DENGUE VIRUS 1; DENGUE VIRUS 2; DENGUE VIRUS 3; DENGUE VIRUS 4; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; FATIGUE; HEADACHE; HUMAN; INFECTION PREVENTION; LOW DRUG DOSE; NONHUMAN; PRODUCT DEVELOPMENT; PROTEIN DOMAIN; PROTEIN TARGETING; REPLICON; REVIEW; SITE DIRECTED MUTAGENESIS; VACCINATION; VACCINE PRODUCTION; VIRUS INACTIVATION; VIRUS PURIFICATION;

DENGUE; DENGUE VACCINES; HUMANS; VACCINES, ATTENUATED; VACCINES, DNA; VACCINES, SYNTHETIC;

EID: 79959328055     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.7.6.14985     Document Type: Review

References (196)

1. Thomas SJ, Strickman D, Vaughn DW. Dengue epidemiology: virus epidemiology, ecology and emergence. Adv Virus Res 2003; 61:235-89. (Pubitemid 137639388)
2. Ayyub M, Khazindar AM, Lubbad EH, Barlas S, Alfi AY, Al-Ukayli S. Characteristics of dengue fever in a large public hospital, Jeddah, Saudi Arabia. J Ayub Med Coll Abbottabad 2006; 18:9-13.
3. Ahmed S, Arif F, Yahya Y, Rehman A, Abbas K, Ashraf S, et al. Dengue fever outbreak in Karachi 2006 - a study of profile and outcome of children under 15 years of age. J Pak Med Assoc 2008; 58:4-8.
4. Dorji T, Yoon IK, Holmes EC, Wangchuk S, Tobgay T, Nisalak A, et al. Diversity and origin of dengue virus serotypes 1, 2 and 3, Bhutan. Emerg Infect Dis 2009; 15:1630-2.
5. Gould EA, Gallian P, De Lamballerie X, Charrel RN. First cases of autochthonous dengue fever and chikungunya fever in France: from bad dream to reality! Clin Microbiol Infect 2010; 16:1702-4.
6. Schmidt-Chanasit J, Haditsch M, Schoneberg I, Gunther S, Stark K, Frank C. Dengue virus infection in a traveller returning from Croatia to Germany. Euro Surveill 2010; 15.
7. Locally acquired Dengue - Key West, Florida 2009-2010. MMWR Morb Mortal Wkly Rep 2010; 59:577-81.
8. Gubler DJ. Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. Trends Microbiol 2002; 10:100-3. (Pubitemid 34119347)
9. Henchal EA, Putnak JR. The dengue viruses. Clin Microbiol Rev 1990; 3:376-96.
10. Rico-Hesse R. Dengue virus virulence and transmission determinants. Curr Top Microbiol Immunol 2010; 338:45-55.
11. Holmes EC, Twiddy SS. The origin, emergence and evolutionary genetics of dengue virus. Infect Genet Evol 2003; 3:19-28. (Pubitemid 36437583)
12. Rico-Hesse R. Microevolution and virulence of dengue viruses. Adv Virus Res 2003; 59:315-41. (Pubitemid 137639369)
13. Jarman RG, Holmes EC, Rodpradit P, Klungthong C, Gibbons RV, Nisalak A, et al. Microevolution of Dengue viruses circulating among primary school children in Kamphaeng Phet, Thailand. J Virol 2008; 82:5494-500. (Pubitemid 351705256)
14. Imrie A, Roche C, Zhao Z, Bennett S, Laille M, Effler P, et al. Homology of complete genome sequences for dengue virus type-1, from dengue-fever- and dengue-haemorrhagic-fever-associated epidemics in Hawaii and French Polynesia. Ann Trop Med Parasitol 2010; 104:225-35.
15. Rico-Hesse R. Dengue virus evolution and virulence models. Clin Infect Dis 2007; 44:1462-6. (Pubitemid 46801591)
16. Burke DS, Nisalak A, Johnson DE, Scott RM. A prospective study of dengue infections in Bangkok. Am J Trop Med Hyg 1988; 38:172-80. (Pubitemid 18036130)
17. Rigau-Perez JG, Clark GG, Gubler DJ, Reiter P, Sanders EJ, Vorndam AV. Dengue and dengue haemorrhagic fever. Lancet 1998; 352:971-7. (Pubitemid 28427290)
18. WHO. Dengue: guidelines for diagnosis, treatment, prevention and control - New edition. Geneva 2009.
19. Soler Rosario Y, Garcia R, Fernandez Sein A. Dengue virus associated hemophagocytic syndrome in children: a case report. Bol Asoc Med P R 2010; 102:49-54.
20. Nasim A. Dengue fever presenting as acute acalculous cholecystitis. J Coll Physicians Surg Pak 2009; 19:531-3.
21. Matlani M, Chakravarti A, Rawal A, Kashyap B, Gurtoo A. Dengue encephalitis: an entity now common in dengue-prone regions. Trop Doct 2009; 39:115-6.
22. Gulati S, Maheshwari A. Atypical manifestations of dengue. Trop Med Int Health 2007; 12:1087-95. (Pubitemid 47421842)
23. Kamath SR, Ranjit S. Clinical features, complications and atypical manifestations of children with severe forms of dengue hemorrhagic fever in South India. Indian J Pediatr 2006; 73:889-95.
24. Nimmannitya S, Thisyakorn U, Hemsrichart V. Dengue haemorrhagic fever with unusual manifestations. Southeast Asian J Trop Med Public Health 1987; 18:398-406.
25. Sabin AB. Research on dengue during World War II. Am J Trop Med Hyg 1952; 1:30-50.
26. Sun W, Edelman R, Kanesa-Thasan N, Eckels KH, Putnak JR, King AD, et al. Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates. Am J Trop Med Hyg 2003; 69:24-31.
27. Edelman R, Wasserman SS, Bodison SA, Putnak RJ, Eckels KH, Tang D, et al. Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am J Trop Med Hyg 2003; 69:48-60.
28. Guy B, Barban V, Mantel N, Aguirre M, Gulia S, Pontvianne J, et al. Evaluation of interferences between dengue vaccine serotypes in a monkey model. Am J Trop Med Hyg 2009; 80:302-11.
29. Endy TP, Nisalak A, Chunsuttitwat S, Vaughn DW, Green S, Ennis FA, et al. Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. J Infect Dis 2004; 189:990-1000. (Pubitemid 38373090)
30. Libraty DH, Acosta LP, Tallo V, Segubre-Mercado E, Bautista A, Potts JA, et al. A prospective nested case-control study of Dengue in infants: rethinking and refining the antibody-dependent enhancement dengue hemorrhagic fever model. PLoS Med 2009; 6:1000171.
31. Thomas SJ, Nisalak A, Anderson KB, Libraty DH, Kalayanarooj S, Vaughn DW, et al. Dengue plaque reduction neutralization test (PRNT) in primary and secondary dengue virus infections: How alterations in assay conditions impact performance. Am J Trop Med Hyg 2009; 81:825-33.
32. Rico-Hesse R, Harrison LM, Salas RA, Tovar D, Nisalak A, Ramos C, et al. Origins of dengue type 2 viruses associated with increased pathogenicity in the Americas. Virology 1997; 230:244-51. (Pubitemid 27211855)
33. Rico-Hesse R. Molecular evolution and distribution of dengue viruses type 1 and 2 in nature. Virology 1990; 174:479-93. (Pubitemid 20060152)
34. Leitmeyer KC, Vaughn DW, Watts DM, Salas R, Villalobos I, de C, et al. Dengue virus structural differences that correlate with pathogenesis. J Virol 1999; 73:4738-47. (Pubitemid 29246733)
35. Cologna R, Rico-Hesse R. American genotype structures decrease dengue virus output from human monocytes and dendritic cells. J Virol 2003; 77:3929-38. (Pubitemid 36350934)
36. Kochel TJ, Watts DM, Halstead SB, Hayes CG, Espinoza A, Felices V, et al. Effect of dengue-1 antibodies on American dengue-2 viral infection and dengue haemorrhagic fever. Lancet 2002; 360:310-2. (Pubitemid 34874726)
37. Fried JR, Gibbons RV, Kalayanarooj S, Thomas SJ, Srikiatkhachorn A, Yoon IK, et al. Serotype-specific differences in the risk of dengue hemorrhagic fever: an analysis of data collected in Bangkok, Thailand from 1994 to 2006. PLoS Negl Trop Dis 2010; 4:617.
38. Nishiura H, Halstead SB. Natural history of dengue virus (DENV)-1 and DENV-4 infections: reanalysis of classic studies. J Infect Dis 2007; 195:1007-13. (Pubitemid 46452106)
39. Guzman MG, Kouri GP, Bravo J, Soler M, Vazquez S, Morier L. Dengue hemorrhagic fever in Cuba, 1981: a retrospective seroepidemiologic study. Am J Trop Med Hyg 1990; 42:179-84.
40. Morens DM. Antibody-dependent enhancement of infection and the pathogenesis of viral disease. Clin Infect Dis 1994; 19:500-12. (Pubitemid 24286955)
41. Stephens HA. HLA and other gene associations with dengue disease severity. Curr Top Microbiol Immunol 2010; 338:99-114.
42. Nguyen TP, Kikuchi M, Vu TQ, Do QH, Tran TT, Vo DT, et al. Protective and enhancing HLA alleles, HLA-DRB1*0901 and HLA-A*24, for severe forms of dengue virus infection, dengue hemorrhagic fever and dengue shock syndrome. PLoS Negl Trop Dis 2008; 2:304.
43. Kalayanarooj S, Gibbons RV, Vaughn D, Green S, Nisalak A, Jarman RG, et al. Blood group AB is associated with increased risk for severe dengue disease in secondary infections. J Infect Dis 2007; 195:1014-7. (Pubitemid 46452107)
44. de la CSB, Kouri G, Guzman MG. Race: a risk factor for dengue hemorrhagic fever. Arch Virol 2007; 152:533-42. (Pubitemid 46363592)
45. Rigau-Perez JG, Laufer MK. Dengue-related deaths in Puerto Rico 1992-1996; diagnosis and clinical alarm signals. Clin Infect Dis 2006; 42:1241-6.
46. Nguyen TH, Nguyen TL, Lei HY, Lin YS, Le BL, Huang KJ, et al. Association between sex, nutritional status, severity of dengue hemorrhagic fever and immune status in infants with dengue hemorrhagic fever. Am J Trop Med Hyg 2005; 72:370-4.
47. Pichainarong N, Mongkalangoon N, Kalayanarooj S, Chaveepojnkamjorn W. Relationship between body size and severity of dengue hemorrhagic fever among children aged 0-14 years. Southeast Asian J Trop Med Public Health 2006; 37:283-8. (Pubitemid 44074325)
48. Stephens HA, Klaythong R, Sirikong M, Vaughn DW, Green S, Kalayanarooj S, et al. HLA-A and -B allele associations with secondary dengue virus infections correlate with disease severity and the infecting viral serotype in ethnic Thais. Tissue Antigens 2002; 60:309-18. (Pubitemid 36020803)
49. Thisyakorn U, Nimmannitya S. Nutritional status of children with dengue hemorrhagic fever. Clin Infect Dis 1993; 16:295-7. (Pubitemid 23047434)
50. Figueiredo MA, Rodrigues LC, Barreto ML, Lima JW, Costa MC, Morato V, et al. Allergies and diabetes as risk factors for dengue hemorrhagic fever: results of a case control study. PLoS Negl Trop Dis 2010; 4:699.
51. Guzman MG, Kouri G, Bravo J, Valdes L, Vazquez S, Halstead SB. Effect of age on outcome of secondary dengue 2 infections. Int J Infect Dis 2002; 6:118-24. (Pubitemid 34793060)
52. Halstead SB. In vivo enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody. J Infect Dis 1979; 140:527-33.
53. Halstead SB, Porterfield JS, O'Rourke EJ. Enhancement of dengue virus infection in monocytes by flavivirus antisera. Am J Trop Med Hyg 1980; 29:638-42. (Pubitemid 10011093)
54. Kurane I, Innis BL, Nimmannitya S, Nisalak A, Meager A, Janus J, et al. Activation of T lymphocytes in dengue virus infections. High levels of soluble interleukin 2 receptor, soluble CD4, soluble CD8, interleukin 2 and interferongamma in sera of children with dengue. J Clin Invest 1991; 88:1473-80.
55. Burke DS, Kliks S. Antibody-dependent enhancement in dengue virus infections. J Infect Dis 2006; 193:601-3. (Pubitemid 43202754)
56. Dejnirattisai W, Jumnainsong A, Onsirisakul N, Fitton P, Vasanawathana S, Limpitikul W, et al. Cross-reacting antibodies enhance dengue virus infection in humans. Science 2010; 328:745-8.
57. Halstead SB, Nimmannitya S, Margiotta MR. Dengue d chikungunya virus infection in man in Thailand 1962-1964. II. Observations on disease in outpatients. Am J Trop Med Hyg 1969; 18:972-83.
58. Halstead SB, Chow JS, Marchette NJ. Immunological enhancement of dengue virus replication. Nat New Biol 1973; 243:24-6.
59. Simmons CP, Dong T, Chau NV, Dung NT, Chau TN, Thao le TT, et al. Early T-cell responses to dengue virus epitopes in Vietnamese adults with secondary dengue virus infections. J Virol 2005; 79:5665-75. (Pubitemid 40548235)
60. Rothman AL. Cellular immunology of sequential dengue virus infection and its role in disease pathogenesis. Curr Top Microbiol Immunol 2010; 338:83-98.
61. Friberg H, Burns L, Woda M, Kalayanarooj S, Endy TP, Stephens HA, et al. Memory CD8(+) T cells from naturally acquired primary dengue virus infection are highly cross-reactive. Immunol Cell Biol 2010.
62. Mathew A, Rothman AL. Understanding the contribution of cellular immunity to dengue disease pathogenesis. Immunol Rev 2008; 225:300-13.
63. Green S, Rothman A. Immunopathological mechanisms in dengue and dengue hemorrhagic fever. Curr Opin Infect Dis 2006; 19:429-36. (Pubitemid 44338101)
64. Duangchinda T, Dejnirattisai W, Vasanawathana S, Limpitikul W, Tangthawornchaikul N, Malasit P, et al. Immunodominant T-cell responses to dengue virus NS3 are associated with DHF. Proc Natl Acad Sci USA 2010; 107:16922-7.
65. Cummings DA, Iamsirithaworn S, Lessler JT, McDermott A, Prasanthong R, Nisalak A, et al. The impact of the demographic transition on dengue in Thailand: insights from a statistical analysis and mathematical modeling. PLoS Med 2009; 6:1000139.
66. Watanaveeradej V, Endy TP, Samakoses R, Kerdpanich A, Simasathien S, Polprasert N, et al. Transplacentally transferred maternal-infant antibodies to dengue virus. Am J Trop Med Hyg 2003; 69:123-8.
67. Jain A, Chaturvedi UC. Dengue in infants: an overview. FEMS Immunol Med Microbiol 2010; 59:119-30.
68. Chau TN, Anders KL, Lien le B, Hung NT, Hieu LT, Tuan NM, et al. Clinical and virological features of Dengue in Vietnamese infants. PLoS Negl Trop Dis 2010; 4:657.
69. Capeding RZ, Brion JD, Caponpon MM, Gibbons RV, Jarman RG, Yoon IK, et al. The incidence, characteristics and presentation of dengue virus infections during infancy. Am J Trop Med Hyg 2010; 82:330-6.
70. Chau TN, Hieu NT, Anders KL, Wolbers M, Lien le B, Hieu LT, et al. Dengue virus infections and maternal antibody decay in a prospective birth cohort study of Vietnamese infants. J Infect Dis 2009; 200:1893-900.
71. Chau TN, Quyen NT, Thuy TT, Tuan NM, Hoang DM, Dung NT, et al. Dengue in Vietnamese infants - results of infection-enhancement assays correlate with age-related disease epidemiology and cellular immune responses correlate with disease severity. J Infect Dis 2008; 198:516-24.
72. Pengsaa K, Luxemburger C, Sabchareon A, Limkittikul K, Yoksan S, Chambonneau L, et al. Dengue virus infections in the first 2 years of life and the kinetics of transplacentally transferred dengue neutralizing antibodies in thai children. J Infect Dis 2006; 194:1570-6. (Pubitemid 44851899)
73. Hammond SN, Balmaseda A, Perez L, Tellez Y, Saborio SI, Mercado JC, et al. Differences in dengue severity in infants, children and adults in a 3-year hospital-based study in Nicaragua. Am J Trop Med Hyg 2005; 73:1063-70. (Pubitemid 43038255)
74. Sangkawibha N, Rojanasuphot S, Ahandrik S, Viriyapongse S, Jatanasen S, Salitul V, et al. Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand I. The 1980 outbreak. Am J Epidemiol 1984; 120:653-69. (Pubitemid 15210730)
75. Nogueira RM, Miagostovich MP, Lampe E, Souza RW, Zagne SM, Schatzmayr HG. Dengue epidemic in the stage of Rio de Janeiro, Brazil 1990-1: co-circulation of dengue 1 and dengue 2 serotypes. Epidemiol Infect 1993; 111:163-70.
76. Witayathawornwong P. DHF in infants, late infants and older children: a comparative study. Southeast Asian J Trop Med Public Health 2005; 36:896-900. (Pubitemid 41635009)
77. Wichmann O, Hongsiriwon S, Bowonwatanuwong C, Chotivanich K, Sukthana Y, Pukrittayakamee S. Risk factors and clinical features associated with severe dengue infection in adults and children during the 2001 epidemic in Chonburi, Thailand. Trop Med Int Health 2004; 9:1022-9.
78. Guzman MG, Kouri G, Valdes L, Bravo J, Vazquez S, Halstead SB. Enhanced severity of secondary dengue-2 infections: death rates in 1981 and 1997 Cuban outbreaks. Rev Panam Salud Publica 2002; 11:223-7.
79. Lye DC, Lee VJ, Sun Y, Leo YS. The benign nature of acute dengue infection in hospitalized older adults in Singapore. Int J Infect Dis 2010; 14:410-3.
80. Roehrig JT, Hombach J, Barrett AD. Guidelines for Plaque-Reduction Neutralization Testing of Human Antibodies to Dengue Viruses. Viral Immunol 2008; 21:123-32. (Pubitemid 351873374)
81. Edelman R, Hombach J. "Guidelines for the clinical evaluation of dengue vaccines in endemic areas": summary of a World Health Organization Technical Consultation. Vaccine 2008; 26:4113-9.
82. Thomas SJ, Hombach J, Barrett A. Scientific consultation on cell mediated immunity (CMI) in dengue and dengue vaccine development. Vaccine 2009; 27:355-68.
83. Hombach J, Cardosa MJ, Sabchareon A, Vaughn DW, Barrett AD. Scientific consultation on immunological correlates of protection induced by dengue vaccines report from a meeting held at the World Health Organization 17-18 November 2005. Vaccine 2007; 25:4130-9.
84. Russell PK, Nisalak A. Dengue virus identification by the plaque reduction neutralization test. J Immunol 1967; 99:291-6.
85. Russell PK, Nisalak A, Sukhavachana P, Vivona S. A plaque reduction test for dengue virus neutralizing antibodies. J Immunol 1967; 99:285-90.
86. Vorndam V, Beltran M. Enzyme-linked immunosorbent assay-format microneutralization test for dengue viruses. Am J Trop Med Hyg 2002; 66:208-12. (Pubitemid 34755655)
87. Guy B, Nougarede N, Begue S, Sanchez V, Souag N, Carre M, et al. Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects. Vaccine 2008; 26:5712-21.
88. Rothman AL, Kanesa-thasan N, West K, Janus J, Saluzzo JF, Ennis FA. Induction of T lymphocyte responses to dengue virus by a candidate tetravalent live attenuated dengue virus vaccine. Vaccine 2001; 19:4694-9. (Pubitemid 32800752)
89. Beckett CG, Tjaden J, Burgess T, Danko JR, Tamminga C, Simmons M, et al. Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial. Vaccine 2010.
90. Koraka P, Benton S, van Amerongen G, Stittelaar KJ, Osterhaus AD. Efficacy of a live attenuated tetravalent candidate dengue vaccine in naive and previously infected cynomolgus macaques. Vaccine 2007; 25:5409-16. (Pubitemid 46977528)
91. Balas C, Kennel A, Deauvieau F, Sodoyer R, Arnaud-Barbe N, Lang J, et al. Different innate signatures induced in human monocyte-derived dendritic cells by wild-type dengue 3 virus, attenuated but reactogenic dengue 3 vaccine virus or attenuated nonreactogenic dengue 1-4 vaccine virus strains. J Infect Dis 2011; 203:103-8.
92. Simmons JS, St. John JH, Reynolds FHK. Experimental studies of dengue. The Philippine Journal of Science 1931; 44:1-252.
93. Schlesinger RW, Gordon I, Frankel JW, Winter JW, Patterson PR, Dorrance WR. Clinical and serologic response of man to immunization with attnuated dengue and yellow fever viruses. JImmunol 1956; 77:352-64.
94. Sabin AB, Schlesinger RW. Production of Immunity to Dengue with Virus Modified by Propagation in Mice. Science 1945; 101:640-2.
95. Bellanti JA, Bourke AT, Buescher EL, Cadigan FC, Cole GA, El Batawi Y, et al. Report of dengue vaccine field trial in the Caribbean 1963: a collaborative study. Bull World Health Organ 1966; 35:93.
96. Halstead SB, Marchette NJ, Diwan AR, Palumbo NE, Putvatana R. Selection of attenuated dengue 4 viruses by serial passage in primary kidney cells. II. Attributes of virus cloned at different dog kidney passage levels. Am J Trop Med Hyg 1984; 33:666-71. (Pubitemid 14053364)
97. Bhamarapravati N, Yoksan S, Chayaniyayothin T, Angsubphakorn S, Bunyaratvej A. Immunization with a live attenuated dengue-2-virus candidate vaccine (16681-PDK 53): clinical, immunological and biological responses in adult volunteers. Bull World Health Organ 1987; 65:189-95. (Pubitemid 17089851)
98. Bhamarapravati N, Sutee Y. Live attenuated tetravalent dengue vaccine. Vaccine 2000; 18:44-7. (Pubitemid 30252002)
99. Sabchareon A, Lang J, Chanthavanich P, Yoksan S, Forrat R, Attanath P, et al. Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children. Pediatr Infect Dis J 2004; 23:99-109. (Pubitemid 38222779)
100. Sabchareon A, Lang J, Chanthavanich P, Yoksan S, Forrat R, Attanath P, et al. Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio and multiple doses. Am J Trop Med Hyg 2002; 66:264-72. (Pubitemid 34756095)
101. Sun W, Cunningham D, Wasserman SS, Perry J, Putnak JR, Eckels KH, et al. Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naive adults. Hum Vaccin 2009; 5:33-40.
102. Kanesa-Thasan N, Edelman R, Tacket CO, Wasserman SS, Vaughn DW, Coster TS, et al. Phase 1 studies of Walter Reed Army Institute of Research candidate attenuated dengue vaccines: selection of safe and immunogenic monovalent vaccines. Am J Trop Med Hyg 2003; 69:17-23.
103. Innis BL, Eckels KH. Progress in development of a live-attenuated, tetravalent dengue virus vaccine by the United States Army Medical Research and Materiel Command. Am J Trop Med Hyg 2003; 69:1-4.
104. Eckels KH, Dubois DR, Putnak R, Vaughn DW, Innis BL, Henchal EA, et al. Modification of dengue virus strains by passage in primary dog kidney cells: preparation of candidate vaccines and immunization of monkeys. Am J Trop Med Hyg 2003; 69:12-6.
105. Simasathien S, Thomas SJ, Watanaveeradej V, Nisalak A, Barberousse C, Innis BL, et al. Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children. Am J Trop Med Hyg 2008; 78:426-33. (Pubitemid 351845193)
106. Lai CY, Hu HP, King CC, Wang WK. Incorporation of dengue virus replicon into virus-like particles by a cell line stably expressing precursor membrane and envelope proteins of dengue virus type 2. J Biomed Sci 2008; 15:15-27.
107. Pang X, Zhang M, Dayton AI. Development of Dengue virus type 2 replicons capable of prolonged expression in host cells. BMC Microbiol 2001; 1:18.
108. Valdes I, Hermida L, Gil L, Lazo L, Castro J, Martin J, et al. Heterologous prime-boost strategy in non-human primates combining the infective dengue virus and a recombinant protein in a formulation suitable for human use. Int J Infect Dis 2010; 14:377-83.
109. Guzman MG, Hermida L, Bernardo L, Ramirez R, Guillen G. Domain III of the envelope protein as a dengue vaccine target. Expert Rev Vaccines 2010; 9:137-47.
110. Brandler S, Ruffie C, Najburg V, Frenkiel MP, Bedouelle H, Despres P, et al. Pediatric measles vaccine expressing a dengue tetravalent antigen elicits neutralizing antibodies against all four dengue viruses. Vaccine 2010; 28:6730-9.
111. Batra G, Raut R, Dahiya S, Kamran N, Swaminathan S, Khanna N. Pichia pastoris-expressed dengue virus type 2 envelope domain III elicits virus-neutralizing antibodies. J Virol Methods 2010; 167:10-6.
112. Valdes I, Hermida L, Martin J, Menendez T, Gil L, Lazo L, et al. Immunological evaluation in nonhuman primates of formulations based on the chimeric protein P64k-domain III of dengue 2 and two components of Neisseria meningitidis. Vaccine 2009; 27:995-1001.
113. Leng CH, Liu SJ, Tsai JP, Li YS, Chen MY, Liu HH, et al. A novel dengue vaccine candidate that induces cross-neutralizing antibodies and memory immunity. Microbes Infect 2009; 11:288-95.
114. Khanam S, Pilankatta R, Khanna N, Swaminathan S. An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity. Vaccine 2009; 27:6011-21.
115. Bernardo L, Fleitas O, Pavon A, Hermida L, Guillen G, Guzman MG. Antibodies induced by dengue virus type 1 and 2 envelope domain III recombinant proteins in monkeys neutralize strains with different genotypes. Clin Vaccine Immunol 2009; 16:1829-31.
116. Izquierdo A, Bernardo L, Martin J, Santana E, Hermida L, Guillen G, et al. Serotype-specificity of recombinant fusion proteins containing domain III of dengue virus. Virus Res 2008; 138:135-8.
117. Babu JP, Pattnaik P, Gupta N, Shrivastava A, Khan M, Rao PV. Immunogenicity of a recombinant envelope domain III protein of dengue virus type-4 with various adjuvants in mice. Vaccine 2008; 26:4655-63.
118. Saejung W, Fujiyama K, Takasaki T, Ito M, Hori K, Malasit P, et al. Production of dengue 2 envelope domain III in plant using TMV-based vector system. Vaccine 2007; 25:6646-54. (Pubitemid 47224986)
119. Chen S, Yu M, Jiang T, Deng Y, Qin C, Qin E. Induction of tetravalent protective immunity against four dengue serotypes by the tandem domain III of the envelope protein. DNA Cell Biol 2007; 26:361-7. (Pubitemid 46981691)
120. Simmons M, Porter KR, Hayes CG, Vaughn DW, Putnak R. Characterization of antibody responses to combinations of a dengue virus type 2 DNA vaccine and two dengue virus type 2 protein vaccines in rhesus macaques. J Virol 2006; 80:9577-85. (Pubitemid 44435632)
121. Mota J, Acosta M, Argotte R, Figueroa R, Mendez A, Ramos C. Induction of protective antibodies against dengue virus by tetravalent DNA immunization of mice with domain III of the envelope protein. Vaccine 2005; 23:3469-76. (Pubitemid 40517122)
122. Hermida L, Bernardo L, Martin J, Alvarez M, Prado I, Lopez C, et al. A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates. Vaccine 2006; 24:3165-71.
123. Simmons M, Burgess T, Lynch J, Putnak R. Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy. Virology 2010; 396:280-8.
124. Wang E, Ni H, Xu R, Barrett AD, Watowich SJ, Gubler DJ, et al. Evolutionary relationships of endemic/epidemic and sylvatic dengue viruses. J Virol 2000; 74:3227-34. (Pubitemid 30143747)
125. Burke DS, Monath TP. Flaviviruses. In: Knipe DM, Mowley PM, Eds. Fields Virology. Philadelphia, PA: Lippincott, Williams, Wilkins 2001; 1043-125.
126. Onlamoon N, Noisakran S, Hsiao HM, Duncan A, Villinger F, Ansari AA, et al. Dengue virus-induced hemorrhage in a nonhuman primate model. Blood 2010; 115:1823-34.
127. Cassetti MC, Durbin A, Harris E, Rico-Hesse R, Roehrig J, Rothman A, et al. Report of an NIAID workshop on dengue animal models. Vaccine 2010; 28:4229-34.
128. Guirakhoo F, Weltzin R, Chambers TJ, Zhang ZX, Soike K, Ratterree M, et al. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. J Virol 2000; 74:5477-85. (Pubitemid 30346579)
129. Guirakhoo F, Pugachev K, Arroyo J, Miller C, Zhang ZX, Weltzin R, et al. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment and antibody responses against wild-type dengue virus isolates. Virology 2002; 298:146-59. (Pubitemid 34734888)
130. Sun W, Nisalak A, Gettayacamin M, Eckels KH, Putnak JR, Vaughn DW, et al. Protection of Rhesus monkeys against dengue virus challenge after tetravalent live attenuated dengue virus vaccination. J Infect Dis 2006; 193:1658-65. (Pubitemid 43839470)
131. Kochel TJ, Raviprakash K, Hayes CG, Watts DM, Russell KL, Gozalo AS, et al. A dengue virus serotype-1 DNA vaccine induces virus neutralizing antibodies and provides protection from viral challenge in Aotus monkeys. Vaccine 2000; 18:3166-73. (Pubitemid 30345698)
132. Putnak RJ, Coller BA, Voss G, Vaughn DW, Clements D, Peters I, et al. An evaluation of dengue type-2 inactivated, recombinant subunit and live-attenuated vaccine candidates in the rhesus macaque model. Vaccine 2005; 23:4442-52. (Pubitemid 40991230)
133. Apt D, Raviprakash K, Brinkman A, Semyonov A, Yang S, Skinner C, et al. Tetravalent neutralizing antibody response against four dengue serotypes by a single chimeric dengue envelope antigen. Vaccine 2006; 24:335-44. (Pubitemid 41790437)
134. Raviprakash K, Apt D, Brinkman A, Skinner C, Yang S, Dawes G, et al. A chimeric tetravalent dengue DNA vaccine elicits neutralizing antibody to all four virus serotypes in rhesus macaques. Virology 2006; 353:166-73. (Pubitemid 44291778)
135. Chen L, Ewing D, Subramanian H, Block K, Rayner J, Alterson KD, et al. A heterologous DNA prime-Venezuelan equine encephalitis virus replicon particle boost dengue vaccine regimen affords complete protection from virus challenge in cynomolgus macaques. J Virol 2007; 81:11634-9. (Pubitemid 47623795)
136. White LJ, Yingsiwaphat V, Wahala W, Parsons M, Fuller L, Collier M, et al. An Alphavirus Replicon Based Dengue Vaccine Is Immunogenic And Protective In Rhesus Macaques And Induces Predominantly Domain III Reactive Neutralizing Antibodies. American Society of Tropical Medicine and Hygeine 2010; 83:247.
137. Holman DH, Wang D, Raviprakash K, Raja NU, Luo M, Zhang J, et al. Two complex, adenovirus-based vaccines that together induce immune responses to all four dengue virus serotypes. Clin Vaccine Immunol 2007; 14:182-9. (Pubitemid 46407071)
138. Raja NU, Holman DH, Wang D, Raviprakash K, Juompan LY, Deitz SB, et al. Induction of bivalent immune responses by expression of dengue virus type 1 and type 2 antigens from a single complex adenoviral vector. Am J Trop Med Hyg 2007; 76:743-51. (Pubitemid 351627719)
139. Raviprakash K, Wang D, Ewing D, Holman DH, Block K, Woraratanadharm J, et al. A tetravalent dengue vaccine based on a complex adenovirus vector provides significant protection in rhesus monkeys against all four serotypes of dengue virus. J Virol 2008; 82:6927-34. (Pubitemid 351977713)
140. Men R, Wyatt L, Tokimatsu I, Arakaki S, Shameem G, Elkins R, et al. Immunization of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a truncated envelope glycoprotein of dengue type 2 virus induced resistance to dengue type 2 virus challenge. Vaccine 2000; 18:3113-22. (Pubitemid 30345693)
141. Putnak R, Barvir DA, Burrous JM, Dubois DR, D'Andrea VM, Hoke CH, et al. Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys. J Infect Dis 1996; 174:1176-84. (Pubitemid 26393894)
142. Putnak R, Cassidy K, Conforti N, Lee R, Sollazzo D, Truong T, et al. Immunogenic and protective response in mice immunized with a purified, inactivated, Dengue-2 virus vaccine prototype made in fetal rhesus lung cells. Am J Trop Med Hyg 1996; 55:504-10. (Pubitemid 26392713)
143. Eckels KH, Putnak R. Formalin-inactivated whole virus and recombinant subunit flavivirus vaccines. Adv Virus Res 2003; 61:395-418. (Pubitemid 137640955)
144. Bernardo L, Izquierdo A, Alvarez M, Rosario D, Prado I, Lopez C, et al. Immunogenicity and protective efficacy of a recombinant fusion protein containing the domain III of the dengue 1 envelope protein in nonhuman primates. Antiviral Res 2008; 80:194-9.
145. Bray M, Men R, Lai CJ. Monkeys immunized with intertypic chimeric dengue viruses are protected against wild-type virus challenge. J Virol 1996; 70:4162-6. (Pubitemid 26157401)
146. Raviprakash K, Porter KR, Kochel TJ, Ewing D, Simmons M, Phillips I, et al. Dengue virus type 1 DNA vaccine induces protective immune responses in rhesus macaques. J Gen Virol 2000; 81:1659-67. (Pubitemid 30427070)
147. Modis Y, Ogata S, Clements D, Harrison SC. A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci USA 2003; 100:6986-91. (Pubitemid 36706380)
148. Modis Y, Ogata S, Clements D, Harrison SC. Structure of the dengue virus envelope protein after membrane fusion. Nature 2004; 427:313-9. (Pubitemid 38133652)
149. Clements DE, Coller BA, Lieberman MM, Ogata S, Wang G, Harada KE, et al. Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys. Vaccine 2010; 28:2705-15.
150. Coller BA, Clements S, Ogata S, Martyak T, Thorne M, Yelmene M, et al. Clinical Development of a Recombinant Subunit Vaccine for Dengue. American Society of Tropical Medicine and Hygeine 2010; 83:248.
151. Kinney RM, Butrapet S, Chang GJ, Tsuchiya KR, Roehrig JT, Bhamarapravati N, et al. Construction of infectious cDNA clones for dengue 2 virus: strain 16681 and its attenuated vaccine derivative, strain PDK-53. Virology 1997; 230:300-8. (Pubitemid 27211861)
152. Butrapet S, Huang CY, Pierro DJ, Bhamarapravati N, Gubler DJ, Kinney RM. Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5′ noncoding region and nonstructural proteins 1 and 3. J Virol 2000; 74:3011-9. (Pubitemid 30143723)
153. Huang CY, Butrapet S, Pierro DJ, Chang GJ, Hunt AR, Bhamarapravati N, et al. Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine. J Virol 2000; 74:3020-8. (Pubitemid 30143724)
154. Huang CY, Butrapet S, Tsuchiya KR, Bhamarapravati N, Gubler DJ, Kinney RM. Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development. J Virol 2003; 77:11436-47. (Pubitemid 37271642)
155. Osorio JE, Partidos CD, Brewoo J, Royals MA, Arguello JJ, Silengo SJ, et al. Towards Developing A Non-Invasive Intradermal Vaccination Strategy With A Tetravalent Dengue Vaccine (Denvax): Immunogenicity And Efficacy Studies In Mice And Non-Human Primates. American Society of Tropical Medicine and Hygeine 2010; 83:247.
156. Osorio JE, Huang CYH, Haller A, Livengood J, Velez ID, George S, et al. Update on Tetravalent DENVax: Preparation for Phase 1 Clinical Trials in the US and Colombia.. American Society of Tropical Medicine and Hygeine 2010; 83:271-2.
157. Durbin AP, Karron RA, Sun W, Vaughn DW, Reynolds MJ, Perreault JR, et al. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3′-untranslated region. Am J Trop Med Hyg 2001; 65:405-13. (Pubitemid 33134570)
158. Durbin AP, Whitehead SS, McArthur J, Perreault JR, Blaney JE Jr, Thumar B, et al. rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic and highly infectious in healthy adult volunteers. J Infect Dis 2005; 191:710-8. (Pubitemid 40271058)
159. Blaney JE Jr, Durbin AP, Murphy BR, Whitehead SS. Development of a live attenuated dengue virus vaccine using reverse genetics. Viral Immunol 2006; 19:10-32.
160. Durbin AP, McArthur J, Marron JA, Blaney JE Jr, Thumar B, Wanionek K, et al. The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers. Hum Vaccin 2006; 2:167-73. (Pubitemid 44422483)
161. Durbin AP, McArthur JH, Marron JA, Blaney JE, Thumar B, Wanionek K, et al. rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naive adults. Hum Vaccin 2006; 2:255-60. (Pubitemid 46025657)
162. McArthur JH, Durbin AP, Marron JA, Wanionek KA, Thumar B, Pierro DJ, et al. Phase I clinical evaluation of rDEN4Delta30-200,201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity. Am J Trop Med Hyg 2008; 79:678-84.
163. Wright PF, Durbin AP, Whitehead SS, Ikizler MR, Henderson S, Blaney JE, et al. Phase 1 trial of the dengue virus type 4 vaccine candidate rDEN4{Delta}30-4995 in healthy adult volunteers. Am J Trop Med Hyg 2009; 81:834-41.
164. Blaney JE Jr, Durbin AP, Murphy BR, Whitehead SS. Targeted mutagenesis as a rational approach to dengue virus vaccine development. Curr Top Microbiol Immunol 2010; 338:145-58.
165. Durbin AP, Kirkpatrick B, Pierce K, Elwood D, Tibery C, Lewis R, et al. Evaluation of the Safety and Immunogenicity of TetraVax-DV, A Live Attenuated Tetravalent Dengue Vaccine. American Society of Tropical Medicine and Hygeine 2010; 83:248.
166. Bancroft WH, Scott RM, Eckels KH, Hoke CH Jr, Simms TE, Jesrani KD, et al. Dengue virus type 2 vaccine: reactogenicity and immunogenicity in soldiers. J Infect Dis 1984; 149:1005-10.
167. Edelman R, Tacket CO, Wasserman SS, Vaughn DW, Eckels KH, Dubois DR, et al. A live attenuated dengue-1 vaccine candidate (45AZ5) passaged in primary dog kidney cell culture is attenuated and immunogenic for humans. J Infect Dis 1994; 170:1448-55. (Pubitemid 24369904)
168. Scott RM, Eckels KH, Bancroft WH, Summers PL, McCown JM, Anderson JH, et al. Dengue 2 vaccine: dose response in volunteers in relation to yellow fever immune status. J Infect Dis 1983; 148:1055-60. (Pubitemid 14206309)
169. Hoke CH Jr, Malinoski FJ, Eckels KH, Scott RM, Dubois DR, Summers PL, et al. Preparation of an attenuated dengue 4 (341750 Carib) virus vaccine. II. Safety and immunogenicity in humans. Am J Trop Med Hyg 1990; 43:219-26. (Pubitemid 20268892)
170. Bancroft WH, Top FH Jr, Eckels KH, Anderson JH Jr, McCown JM, Russell PK. Dengue-2 vaccine: virological, immunological and clinical responses of six yellow fever-immune recipients. Infect Immun 1981; 31:698-703. (Pubitemid 11146250)
171. Lang J, Saville M, Guy B. Update on the Phase III Stage Sanofi Pasteur Recombinant Tetravalent Dengue Vaccine. American Society of Tropical Medicine and Hygeine 2010; 83:29.
172. Jones T. Technology evaluation: ChimeriVax-DEN, Acambis/Aventis. Curr Opin Mol Ther 2004; 6:443-50.
173. Guy B, Guirakhoo F, Barban V, Higgs S, Monath TP, Lang J. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine 2010; 28:632-49.
174. Guirakhoo F, Kitchener S, Morrison D, Forrat R, McCarthy K, Nichols R, et al. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum Vaccin 2006; 2:60-7. (Pubitemid 43927159)
175. Lang J. Recent progress on sanofi pasteur's dengue vaccine candidate. J Clin Virol 2009; 46:20-4.
176. Morrison D, Legg TJ, Billings CW, Forrat R, Yoksan S, Lang J. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. J Infect Dis 2010; 201:370-7.
177. Johnson BW, Chambers TV, Crabtree MB, Bhatt TR, Guirakhoo F, Monath TP, et al. Growth characteristics of ChimeriVax-DEN2 vaccine virus in Aedes aegypti and Aedes albopictus mosquitoes. Am J Trop Med Hyg 2002; 67:260-5. (Pubitemid 35178349)
178. Johnson BW, Chambers TV, Crabtree MB, Guirakhoo F, Monath TP, Miller BR. Analysis of the replication kinetics of the ChimeriVax-DEN 1, 2, 3, 4 tetravalent virus mixture in Aedes aegypti by real-time reverse transcriptase-polymerase chain reaction. Am J Trop Med Hyg 2004; 70:89-97. (Pubitemid 39220522)
179. Brandler S, Brown N, Ermak TH, Mitchell F, Parsons M, Zhang Z, et al. Replication of chimeric yellow fever virus-dengue serotype 1-4 virus vaccine strains in dendritic and hepatic cells. Am J Trop Med Hyg 2005; 72:74-81. (Pubitemid 41270311)
180. Higgs S, Vanlandingham DL, Klingler KA, McElroy KL, McGee CE, Harrington L, et al. Growth characteristics of ChimeriVax-Den vaccine viruses in Aedes aegypti and Aedes albopictus from Thailand. Am J Trop Med Hyg 2006; 75:986-93. (Pubitemid 351627554)
181. Guirakhoo F, Pugachev K, Zhang Z, Myers G, Levenbook I, Draper K, et al. Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J Virol 2004; 78:4761-75. (Pubitemid 38501097)
182. Guy B. Immunogenicity of sanofi pasteur tetravalent dengue vaccine. J Clin Virol 2009; 46:16-9.
183. Galan F, Forrat R, Zambrano, Betzana, Bouckenooghe A, Lang J, Dayan G. Priming Effect of Previous Japanese Encephalitis Vaccination on Humoral Immune Response to Tetravalent Dengue Vaccine. American Society of Tropical Medicine and Hygeine 2010; 83:248.
184. Cardosa MJ. Dengue vaccine design: issues and challenges. Br Med Bull 1998; 54:395-405. (Pubitemid 28342663)
185. Guy B, Almond JW. Towards a dengue vaccine: progress to date and remaining challenges. Comp Immunol Microbiol Infect Dis 2008; 31:239-52. (Pubitemid 351315114)
186. Hatch S, Mathew A, Rothman A. Dengue vaccine: opportunities and challenges. IDrugs 2008; 11:42-5.
187. Monath TP. Dengue and yellow fever - challenges for the development and use of vaccines. N Engl J Med 2007; 357:2222-5. (Pubitemid 350190752)
188. Stephenson JR. Developing vaccines against flavivirus diseases: past success, present hopes and future challenges. Novartis Found Symp 2006; 277:193-201.
189. Raviprakash K, Defang G, Burgess T, Porter K. Advances in dengue vaccine development. Hum Vaccin 2009; 5:520-8.
190. Thomas SJ. The necessity and quandaries of dengue vaccine development. J Infect Dis 2011; 203:299-303.
191. Seligman SJ, Gould EA. Live flavivirus vaccines: reasons for caution. Lancet 2004; 363:2073-5. (Pubitemid 38781111)
192. Seligman SJ, Gould EA. Safety concerns with regard to live attenuated flavivirus vaccines. J Infect Dis 2008; 198:794-5.
193. Guy B, Guirakhoo F, Watson M, Higgs S, Monath TP. Safety of flavivirus chimeric vaccines: answer to Ishikawa, et al. Vaccine 2008; 26:4107-8.
194. Monath TP, Kanesa-Thasan N, Guirakhoo F, Pugachev K, Almond J, Lang J, et al. Recombination and flavivirus vaccines: a commentary. Vaccine 2005; 23:2956-8. (Pubitemid 40462433)
195. Murphy BR, Blaney JE Jr, Whitehead SS. Arguments for live flavivirus vaccines. Lancet 2004; 364:499-500.
196. de Silva A, Messer W. Arguments for live flavivirus vaccines. Lancet 2004; 364:500.